Pulmatrix, Inc. (PULM)
NASDAQ: PULM · Real-Time Price · USD
5.38
-0.25 (-4.44%)
At close: Aug 1, 2025, 4:00 PM
5.39
+0.01 (0.19%)
After-hours: Aug 1, 2025, 4:00 PM EDT

Company Description

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States.

The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine.

It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds.

The company was founded in 2003 and is headquartered in Framingham, Massachusetts.

Pulmatrix, Inc.
Pulmatrix logo
CountryUnited States
Founded2003
IndustryBiotechnology
SectorHealthcare
Employees2
CEOPeter Ludlum

Contact Details

Address:
945 Concord Street, Suite 1217
Framingham, Massachusetts 01701
United States
Phone(888) 355-4440
Websitepulmatrix.com

Stock Details

Ticker SymbolPULM
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001574235
CUSIP Number74584P301
ISIN NumberUS74584P3010
Employer ID46-1821392
SIC Code2834

Key Executives

NamePosition
Peter Ludlum CMA, MBAInterim Chief Executive Officer and Interim Chief Financial Officer
Dr. Alexander M. Klibanov Ph.D.Founder

Latest SEC Filings

DateTypeTitle
Jun 16, 2025425Filing
Jun 16, 20258-KCurrent Report
May 15, 202510-QQuarterly Report
May 15, 20258-KCurrent Report
May 9, 2025EFFECTNotice of Effectiveness
May 9, 2025424B3Prospectus
May 7, 2025S-4/AFiling
Apr 17, 2025S-4/AFiling
Apr 10, 20258-KCurrent Report
Apr 8, 20258-KCurrent Report